

[ ORIGINAL ARTICLE ]

## Perforation and Postoperative Bleeding Associated with Endoscopic Submucosal Dissection in Colorectal Tumors: An Analysis of 398 Lesions Treated in Saga, Japan

Koji Yamamoto<sup>1,2</sup>, Ryo Shimoda<sup>1</sup>, Shinichi Ogata<sup>2</sup>, Megumi Hara<sup>3</sup>, Yoichiro Ito<sup>1,2</sup>, Naoyuki Tominaga<sup>2</sup>, Atsushi Nakayama<sup>1,2</sup>, Yasuhisa Sakata<sup>1</sup>, Nanae Tsuruoka<sup>1</sup>, Ryuichi Iwakiri<sup>1</sup> and Kazuma Fujimoto<sup>1</sup>

### Abstract:

**Objective** The aim of this study was to clarify the safety of colorectal endoscopic submucosal dissection (ESD) during the era of health insurance coverage starting from April 2012 in Japan.

**Methods** Between April 2012 and May 2016, ESD was applied to 398 lesions in 373 patients. Risk factors for serious complications of colorectal ESD, perforation and post-ESD bleeding, were evaluated focusing on the resected specimen size, location, growth pattern, invasion depth, histopathology, postoperative clipping, and procedure time. In addition, the relationship between serious complications and patients' background characteristics was analyzed.

**Results** Among 373 patients, perforation occurred in 12 patients and post-ESD bleeding in 19 patients. A univariate analysis showed that the risk factors for perforation were the lesion size, the resected specimen size, and a long operation time. A multivariate analysis showed that a long operation time was a risk factor for perforation during colorectal ESD. A univariate analysis indicated that significant risk factors for postoperative bleeding were a long operation time, rectal lesion, and cancer. All patients with serious complications were treated by an endoscopic procedure without blood transfusion or the need to convert to open surgery.

**Conclusion** The present study suggests that colorectal ESD may be accepted with relative safety in Japan as a common therapeutic approach for early colorectal cancer.

**Key words:** serious complications, clip, colorectal cancer, multivariate analysis

(Intern Med 57: 2115-2122, 2018)

(DOI: 10.2169/internalmedicine.9186-17)

### Introduction

Endoscopic mucosal resection (EMR) of colorectal lesions has become widely accepted as a standard procedure (1-7). EMR for colorectal lesions exceeding 20 mm in diameter sometimes results in piecemeal resection (8-11). Because of high recurrence rates (around 5-20%) after piecemeal resection (12-17), en-bloc resection is required for curative treatment with an accurate histopathological evaluation (8-11). This limitation of EMR has been overcome by the develop-

ment of endoscopic submucosal dissection (ESD) in the stomach and colon (18-23). However, the technical difficulty of performing ESD for colorectal lesions, given the thin intestinal wall, can induce frequent complications, particularly perforation and postoperative delayed bleeding.

Since June 2009, colorectal ESD has been performed in Japan in accordance with the advanced medical treatment system approved by the Japanese Ministry of Health, Labour and Welfare. Colorectal ESD was distinguished from gastric and esophageal ESD because of the associated high complication rates. In April 2012, however, colorectal ESD was in-

<sup>1</sup>Departments of Internal Medicine, Saga Medical School, Saga Medical School, Japan, <sup>2</sup>Department of Gastroenterology, Saga Prefectural Medical Center, Japan and <sup>3</sup>Departments of Preventive Medicine, Saga Medical School, Saga Medical School, Japan

Received: March 14, 2017; Accepted: September 20, 2017; Advance Publication by J-STAGE: March 30, 2018

Correspondence to Dr. Ryo Shimoda, shimodar@cc.saga-u.ac.jp

cluded in health insurance coverage in Japan because of the accumulation of experience with a relatively low complication rate under advanced medical treatment systems (19, 24). Since colorectal ESD was approved for health insurance coverage in April 2012, ESD for colorectal lesions has been applied more often in Japan.

The assessment and prediction of risks of complications after health insurance coverage in Japan may provide important, useful information for colorectal ESD. Several studies have assessed the risk factors for perforation during colorectal ESD and postoperative bleeding (25-32), but few have assessed the risk factors for complications after health insurance coverage started in Japan (24). The aim of the present study was to clarify the safety of colorectal ESD in Japan after April 2012.

## Materials and Methods

### Patients

Between April 2012 and May 2016, colorectal ESD was performed for 398 lesions in 381 patients in Saga Medical School and Saga-ken Medical Centre Koseikan: 250 lesions in Saga Medical School and 148 lesions in Saga-Ken Medical Centre Koseikan. All lesions were treated under the Japanese national health insurance system. The indications for ESD for colorectal lesions were identical to those established in previous reports from other institutions (1, 33, 34) with Japanese health insurance. The pre-operation indications for ESD were the presence of colorectal neoplasms with a tumor size of 2-5 cm. Indications were determined with magnifying endoscopy and included the following characteristics:

- Large (>20 mm in diameter) lesions (possibly indicated for endoscopic treatment but difficult to treat with en-bloc resection using the snare device), including lesions suspected of having submucosal invasion and/or exhibiting the Vi pit pattern with magnifying endoscopy
- Mucosal lesions with fibrosis
- Local residual early cancer after endoscopic resection
- Sporadic localized tumor with chronic inflammation, such as ulcerative colitis

### ESD procedures

ESD was performed using the following procedures, as previously described (19, 21): Hypertonic sodium epinephrine and/or sodium hyaluronate were injected into the submucosal layer around the lesion to raise the mucosal layer. An incision into the mucosa was performed outside the target lesion. The subsequent submucosal dissection of the lesion was performed with a Dual Knife (Olympus Medical Systems, Tokyo, Japan) and/or a Flush Knife-BT (ball tip; Fujifilm, Tokyo, Japan). Regarding anticoagulants and/or antiplatelet drugs, their continued use or cancellation was decided according to the Japan Gastroenterological Endoscopy Society (JGES) guidelines (35, 36).

### Perforation during ESD and postoperative bleeding

Perforation was diagnosed endoscopically and/or by the presence of free air on plain radiography and/or computed tomography (CT) just after ESD. Perforations detected during the ESD procedure were immediately closed with a metal clip (37), and the patient was given antibiotics. Postoperative bleeding was defined as clinical evidence of bleeding after ESD requiring special measures for hemostasis and/or decreases in the hemoglobin level by  $\geq 2.0$  g/dL in comparison with the last preoperative level (38). Bleeding during the ESD procedure was not considered postoperative bleeding.

### Data analyses

The clinical record, endoscopic images, endoscopic report, and histopathological report were reviewed for all patients. Patients with perforation or postoperative bleeding were retrospectively evaluated regarding the following factors: i) patient-related factors, including sex, age and daily usage of anticoagulants and/or antiplatelet drugs; ii) tumor- and treatment-related factors, including the location of the tumor, the size of the resected specimens, and the operation time; iii) co-morbidities, including cerebrovascular disease, ischemic heart disease, chronic liver damage, chronic renal failure, hyperuricemia, hypertension, and diabetes mellitus.

Data were analyzed using the  $\chi^2$  test followed by a multivariate logistic regression analysis to evaluate the effects of independent variables with adjustments for the effects of each of the other factors with the IBM SPSS Statistic software program (International Business Machines, Armonk, USA). Differences of  $p < 0.05$  were considered significant.

## Results

The characteristics of all patients who underwent ESD for colorectal lesions under the Japan national health insurance system during 2012-2016 were as follows (Table 1): mean age  $68.7 \pm 9.9$  years (range 25-90 years); resected specimen size  $35.0 \pm 13.6$  mm (range 23-65 mm); and operation time  $74.0 \pm 56.2$  min (range 20-427 min). Perforation during ESD occurred in 12 of the 398 patients (3.0%). All patients with perforation were treated by endoscopic clipping without the need for laparotomy. The perforation rate was not affected by age, sex, or the use of anticoagulants and/or antiplatelet drugs.

Tumor and treatment-related factors of perforation during ESD are shown in Table 2. A univariate analysis indicated that both the lesion size (28.3 vs. 38.4 mm,  $p < 0.05$ ) and the resected specimen size (34.8 vs. 44.5 mm,  $p < 0.05$ ) were significantly larger in patients with perforation. The operation time for ESD was significantly longer in patients with perforation (71.4 vs. 159.2 min,  $p < 0.05$ ). The operation time included the time for intraoperative hemostasis and the time for clipping to close intraoperative perforation. The tumor location, invasion depth, histological type, and closure with

**Table 1. Results of a Univariate Analysis of Patient-related Factors for Perforation during Colorectal Endoscopic Submucosal Dissection.**

Characteristics	Total	Perforation (+)	Perforation (-)	p
Number of patients	398	12 (3%)	386 (97%)	
Age (years; mean±SD)	68.7±9.9	70.8±8.1	68.6±10	N.S.
Sex				
Male	249	5 (2.0%)	244 (98.0%)	N.S.
Female	149	7 (4.7%)	142 (95.3%)	
Anticoagulants and/or antiplatelet drugs				
(+)	50	3 (6%)	47 (94%)	N.S.
(-)	348	9 (2.6%)	339 (97.4%)	

SD: standard deviation, N.S.: not significant

**Table 2. Results of a Univariate Analysis of Tumor- and Treatment-related Factors for Perforation during Colorectal Endoscopic Submucosal Dissection.**

Factors	Total	Perforation (+)	Perforation (-)	p
Number of patients	398	12	387	
Tumor location				
Colon	290	10 (3.4%)	280 (96.6%)	N.S.
Rectum	108	2 (1.9%)	106 (98.1%)	
Lesion size (mm)	28.6±14.2	38.4±13.8	28.3±14.1	<0.05
Resected size (mm)	35.0±13.6	44.5±15.2	34.8±13.5	<0.05
Operation time (min)	74.0±56.2	159.2±119.8	71.4±51.2	<0.05
Invasion morphology				
Superficial	328	8 (2.4%)	320 (97.6%)	N.S.
Protruded	69	4 (5.8%)	65 (94.2%)	
Histological type				
Adenoma	208	3 (1.4%)	205 (98.6%)	N.S.
Cancer	189	9 (4.8%)	180 (95.2%)	
Closure with hemoclips				
Yes	129	6 (4.7%)	123 (95.3%)	N.S.
No	269	6 (2.2%)	263 (97.8%)	

N.S.: not significant

a hemoclip were not risk factors for perforation during ESD. Table 3 indicates whether or not perforation during ESD was exacerbated by co-morbidities, including cerebral vessel disease, ischemic heart disease, chronic liver damage, chronic renal dysfunction, hyperuricemia, hypertension, and diabetes mellitus. These co-morbidities were not risk factors for perforation during ESD. A multivariate logistic regression analysis in Table 4 revealed that a long operation time was an independent risk factor for perforation ( $p<0.001$ ).

Post-ESD operative bleeding occurred in 19 of the 398 patients (4.8%). All cases of postoperative bleeding were successfully treated by an endoscopic procedure that entailed metal clipping and/or electrocoagulation. As indicated in Table 5, sex, age, and the use of anticoagulants and/or antiplatelet drugs were not risk factors for post-ESD bleeding.

Table 6 shows the tumor- and treatment-related factors of postoperative bleeding associated with ESD. A univariate analysis indicated that the tumor location (colon 3.1% vs. rectum 9.3%,  $p<0.05$ ), histological type (adenoma 1.9% vs.

adenocarcinoma 7.9%,  $p<0.05$ ), and closure with a hemoclip ("yes" 0.8% vs. "no" 6.7%,  $p<0.05$ ) were significantly associated with post-ESD bleeding. A large lesion size (28.2 vs. 35.6 mm,  $p<0.05$ ) and the long ESD operation time (71.6 vs. 123.0 min,  $p<0.05$ ) were risk factors for post-ESD bleeding. Postoperative bleeding associated with ESD was influenced by neither the invasion depth nor the resected size. As indicated in Table 7, post-ESD bleeding was not affected by co-morbidities, including cerebral vessel diseases, ischemic heart disease, chronic liver damage, chronic renal dysfunction, hyperuricemia, hypertension, or diabetes mellitus, indicating that these co-morbidities were not risk factors for postoperative bleeding. As shown in Table 8, a multivariate logistic regression analysis revealed that a long ESD operation time, a rectal lesion, and histological malignancy were independent risk factors for post-ESD bleeding ( $p<0.05$  for each).

The complication rate of the trainees, who had experienced less than 50 ESD cases, was 10.7% (perforation

**Table 3. Results of a Univariate Analysis of Co-morbidities in Patients with Perforation during Colorectal Endoscopic Submucosal Dissection.**

Factors	Total	Perforation (+)	Perforation (-)	p
Number of patients	398	12	387	
Cerebral vessel diseases				
(+)	30	0	30 (100%)	N.S.
(-)	368	12 (3.3%)	356 (96.7%)	
Ischemic heart disease				
(+)	46	3 (6.5%)	43 (93.5%)	N.S.
(-)	352	9 (2.6%)	343 (97.4%)	
Chronic liver damage				
(+)	23	2 (8.7%)	21 (91.3%)	N.S.
(-)	375	10 (2.7%)	365 (97.3%)	
Chronic renal dysfunction				
(+)	14	2 (14.3%)	12 (85.7%)	N.S.
(-)	384	10 (2.6%)	374 (97.4%)	
Hyperuricemia				
(+)	31	2 (6.5%)	29 (93.5%)	N.S.
(-)	367	10 (2.7%)	357 (97.3%)	
Hypertension				
(+)	171	5 (2.9%)	166 (97.1%)	N.S.
(-)	227	7 (3.1%)	220 (96.9%)	
Diabetes mellitus				
(+)	51	2 (3.9%)	49 (96.1%)	N.S.
(-)	347	10 (2.9%)	337 (97.1%)	

N.S.: not significant

**Table 4. Results of a Multivariable Logistic Regression Analysis of Factors Associated with Perforation during Colorectal Endoscopic Submucosal Dissection.**

Variable	Odds ratio	95% CI	p
Lesion size	-		N.S.
Operation time	-		<0.001
Closure with hemoclip	3.49	0.96-12.71	0.058

CI: confidence interval, N.S.: not significant

2.4%, 2/84 cases; postoperative bleeding 8.3%, 7/84 cases), which was not significantly higher than that of the experienced endoscopists. The mean operation time of the trainees was 87.5 minutes, which was relatively long, but not significantly longer than that of the experienced surgeons.

## Discussion

This study evaluated the rates of serious complications (perforation 3.0%, 12/398 cases; postoperative bleeding 4.8%, 19/398 cases) following colorectal ESD in Saga, Japan. The rate of perforation during colorectal ESD was reported to be 1.4-10.4% (26-33, 39-44). The complication rate was high during the early period when ESD was performed in a clinical study in 2007 (10.4%) (43). When colorectal ESD was performed in accordance with the advanced medical treatment system (No. 78) approved by the Japanese

Ministry of Health, Labour and Welfare in June 2009, however, the rate of perforation was lower, as the procedure was performed cautiously and only by experienced endoscopists. Most studies that reported perforation associated with ESD in Japan included subjects who received the procedure under the advanced medical treatment system (2009-2012), and the number of such subjects under health insurance coverage since 2012 was limited. In this study, the perforation rate was almost equivalent to that in other reports (26-34, 39-47). All cases with perforation in this study were treated conservatively with endoscopy, as previously reported in other institutes (26-32, 36-49).

The rate of postoperative bleeding in colorectal ESD was reported to be 0-12.0% (15, 16, 31, 32, 39-45). The report with the highest complication rate (12.0%) included subjects with mild bleeding that did not require endoscopic hemostasis (44). The rate of postoperative bleeding in other studies ranged from 0% to 12.0% (15, 16, 31, 32, 39-45), which was slightly higher than in the present study. The present study included patients who required endoscopic hemostasis. The reason for the relatively low rate of postoperative bleeding was unclear, as prophylactic endoscopic therapy for bleeding was not applied routinely in the present study. All patients with bleeding in the present study were treated by the endoscopic procedure (1, 50) without blood transfusion or a need to convert to a surgical operation.

The serious complication rates, including perforation and bleeding, in colorectal ESD performed by trainees described

**Table 5. Results of a Univariate Analysis of Patient-related Factors in Postoperative Bleeding after Colorectal Endoscopic Submucosal Dissection.**

Factors	Total	Present	Absent	p
Number of patients	398	19	379	
Age (years), mean±SD	68.7±9.9	69.1±7.2	68.7±10.1	N.S.
Sex				
Male	249	11 (4.4%)	238 (95.6%)	N.S.
Female	149	8 (5.4%)	141 (94.6%)	N.S.
Anticoagulants and/or antiplatelet drugs				
Yes	50	2 (4%)	48 (96%)	N.S.
No	348	17 (4.9%)	331 (95.1%)	N.S.

SD: standard deviation, N.S.: not significant

**Table 6. Results of a Univariate Analysis of Tumor- and Treatment-related Factors and Postoperative Bleeding after Colorectal Endoscopic Submucosal Dissection.**

Factors	Total	Present	Absent	p
Number of patients	398	19	379	
Tumor location				
Colon	290	9 (3.1%)	281 (96.9%)	<0.05
Rectum	108	10 (9.3%)	98 (90.7%)	
Lesion size (mm)	35.6±20.2	28.2±13.7		<0.05
Resected size (mm)	40.7±19.8	34.8±13.2		N.S.
Operation time (min)	123.0±108.5	71.6±51.4		<0.05
Invasion morphology				
Superficial	328	13 (4.0%)	315 (96%)	N.S.
Protruded	69	6 (8.7%)	63 (91.3%)	
Histological type				
Adenoma	209	4 (1.9%)	205 (98.1%)	<0.05
Carcinoma	189	15 (7.9%)	174 (92.1%)	
Closure with hemoclips				
Yes	129	1 (0.8%)	128 (99.2%)	<0.05
No	269	18 (6.7%)	251 (93.3%)	

N.S.: not significant

in several reports in Japan have been controversial (46, 51-53); however, the operation time of the trainees was relatively long during the ESD procedure in all of these papers. The serious complication rates of the trainees in the present study were not different in 84 out of the 381 colorectal ESD patients, in whom ESD was performed under the coaching of experienced endoscopists. As a result, the rates of serious complications among the trainees in the present study did not differ substantially from those observed for experienced endoscopists.

The present study indicated that the serious complications of perforation and postoperative bleeding occurred in about 5% of patients associated with the colorectal ESD. All patients with serious complications were treated by endoscopic procedures, which indicated that colorectal ESD under health insurance coverage was a relatively safe procedure. The risk factor for perforation was a prolonged procedure time, and the risk factors for postoperative bleeding were a prolonged procedure time, tumor location in the rectum, and

definitive colon cancer with a pathological diagnosis. Previous studies indicated several risk factors for serious complications with the colorectal ESD including the tumor location, fibrosis of the lesion, difficult endoscopic operability, and rich vascularity (27, 40, 47, 51, 54-62) The present retrospective study did not indicate these factors to be risk factors for serious complications, so further studies may be required to assess the reasons for the discrepancies in these findings. A prolonged procedure time being recognized as a risk factor in the present study was probably due to the difficulties associated with ESD, including those based on the tumor location, fibrosis, and difficult endoscopic operability, as previously reported.

In conclusion, most of the previous studies in Japan included patients who underwent colorectal ESD under special conditions in particular hospitals. The present study suggested that colorectal ESD may be relatively safely applied to treat early colorectal cancer as a common therapeutic approach.



**Table 7. Results of a Univariate Analysis of Co-morbidities in Patients with Postoperative Bleeding after Colorectal Endoscopic Submucosal Dissection.**

Co-morbidity	Total	Present	Absent	p
Number of patients	398	19	379	
Cerebral vessel diseases				
(+)	30	2 (6.7%)	28 (93.3%)	N.S.
(-)	368	17 (4.6%)	351 (95.4%)	
Ischemic heart disease				
(+)	46	2 (4.3%)	44 (95.7%)	N.S.
(-)	352	17 (4.8%)	335 (95.2%)	
Chronic liver damage				
(+)	23	3 (13%)	20 (87%)	N.S.
(-)	375	16 (4.3%)	359 (95.7%)	
Chronic renal dysfunction				
(+)	14	2 (14.3%)	12 (85.7%)	N.S.
(-)	384	17 (4.4%)	367 (95.6%)	
Hyperuricemia				
(+)	31	2 (6.5%)	29 (93.5%)	N.S.
(-)	367	17 (4.6%)	350 (95.4%)	
Hypertension				
(+)	171	8 (4.7%)	163 (95.3%)	N.S.
(-)	227	11 (4.8%)	216 (95.2%)	
Diabetes mellitus				
(+)	51	3 (5.9%)	48 (94.1%)	N.S.
(-)	347	16 (4.6%)	331 (95.4%)	

N.S.: not significant

**Table 8. Results of a Multivariable Logistic Regression Analysis of Factors Associated Postoperative Bleeding after Colorectal Endoscopic Submucosal Dissection.**

Variable	Odds ratio	95% CI	P
Operation time	-		0.006
Location (rectum)	2.69	1.02-7.06	0.045
Histological type (carcinoma)	3.4	1.08-10.71	0.037

CI: confidence interval

The authors state that they have no Conflict of Interest (COI).

## References

1. Tanaka S, Kashida H, Saito Y, et al. JGES guidelines for colorectal endoscopic submucosal dissection/endoscopic mucosal resection. *Dig Endosc* **27**: 417-434, 2015.
2. Puli SR, Kakugawa Y, Gotoda T, Antillon D, Saito Y, Antillon MR. Meta-analysis and systematic review of colorectal endoscopic mucosal resection. *World J Gastroenterol* **15**: 4273-4277, 2009.
3. Ahmad NA, Kochman ML, Long WB, Furth EE, Ginsberg GG. Efficacy, safety, and clinical outcomes of endoscopic mucosal resection: a study of 101 cases. *Gastrointest Endosc* **55**: 390-396, 2002.
4. Yokota T, Sugihara K, Yoshida S. Endoscopic mucosal resection for colorectal neoplastic lesions. *Dis Colon Rectum* **37**: 1108-1111, 1994.
5. Kudo S. Endoscopic mucosal resection of flat and depressed types of early colorectal cancer. *Endoscopy* **25**: 455-461, 1993.
6. Saito Y, Fujii T, Kondo H, et al. Endoscopic treatment for laterally spreading tumors in colon. *Endoscopy* **33**: 682-686, 2001.
7. Kudo S, Kashida H, Tamura T, et al. Colonoscopic diagnosis and management of nonpolypoid early colorectal cancer. *World J Surg* **24**: 1081-1090, 2000.
8. Tanaka S, Haruma K, Oka S, et al. Clinicopathologic features and endoscopic treatment of superficially spreading colorectal neoplasms larger than 20 mm. *Gastrointest Endosc* **54**: 62-66, 2001.
9. Hotta K, Fujii T, Saito Y, Matsuda T. Local recurrence after endoscopic resection of colorectal tumors. *Int J Colorectal Dis* **24**: 225-230, 2009.
10. Saito Y, Fukuzawa M, Matsuda T, et al. Clinical outcomes of endoscopic submucosal dissection versus endoscopic mucosal resection of large colorectal tumors as determined by curative resection. *Surg Endosc* **24**: 343-352, 2010.
11. Nakajima T, Saito Y, Tanaka S, et al. Current status of endoscopic resection strategy for large, early colorectal neoplasia in Japan. *Surg Endosc* **27**: 3262-3270, 2013.
12. Binmoeller KF, Bohnacker S, Seifert H, Thonke F, Valdeyar H, Soehendra N. Endoscopic snare excision of "giant" colorectal polyps. *Gastrointest Endosc* **43**: 183-188, 1996.
13. Higaki S, Hashimoto S, Harada K, et al. Long-term follow-up of large flat colorectal tumors resected endoscopically. *Endoscopy* **35**: 845-849, 2003.
14. Tamura S, Nakajo K, Yokoyama Y, et al. Evaluation of endoscopic mucosal resection for laterally spreading rectal tumors. *Endoscopy* **36**: 306-312, 2004.
15. Hurlstone DP, Sanders DS, Cross SS, et al. Colonoscopic resection of lateral spreading tumors; a prospective analysis of endoscopic mucosal resection. *Gut* **53**: 1334-1339, 2004.
16. Tanaka S, Oka S, Chayama K. Endoscopic mucosal resection for superficial early colorectal carcinoma - indication, choice of methods and outcome. *Nihon Syoukaki Naishikyoku Gakkai Zasshi (J Jpn So Gastroenterol Endosc)* **46**: 243-252, 2004 (in Japanese, ab-

- stract in English ).
17. Makazu M, Sakamoto T, So E, et al. Relationship between indeterminate or positive lateral margin and local recurrence after endoscopic resection of colorectal polyps. *Endosc Int Open* **3**: 252-257, 2015.
  18. Watanabe K, Ogata S, Kawazoe S, et al. Clinical outcomes of EMR for gastric tumors: historical pilot evaluation between endoscopic submucosal dissection and conventional mucosal resection. *Gastrointest Endosc* **63**: 776-782, 2006.
  19. Saito Y, Yamada M, So E, et al. Colorectal endoscopic submucosal dissection: Technical advantage compared to endoscopic mucosal resection and minimally invasive surgery. *Dig Endosc* **26**: 52-61, 2014.
  20. Ohata K, Nonaka K, Minato Y, et al. Endoscopic submucosal dissection for large colorectal tumor in a Japanese general hospital. *J Oncol* **2013**: 218670, 2013.
  21. Sakamoto T, Mori G, Yamada M, et al. Endoscopic submucosal dissection for colorectal neoplasms: a review. *World J Gastroenterol* **20**: 16153-16158, 2014.
  22. Yamanouchi K, Ogata S, Sakata Y, et al. Effect of additional surgery after noncurative endoscopic submucosal dissection for early gastric cancer. *Endosc Int Open* **4**: 24-29, 2016.
  23. Aoki S, Sakata Y, Shimoda R, et al. High-density collagen patch prevents stricture after endoscopic circumferential submucosal dissection of the esophagus: a porcine model. *Gastrointest Endosc* **85**: 1076-1085, 2017 (Epub ahead of print).
  24. Saito Y, Kawano H, Takeuchi Y, et al. Current status of colorectal endoscopic submucosal dissection in Japan and other Asian countries: progressing towards technical standardization. *Dig Endosc* **24**: 67-72, 2012.
  25. Shimoda R, Sakata Y, Fujise T, et al. The adenoma miss rate of blue-laser imaging vs. white-light imaging during colonoscopy: a randomized tandem trial. *Endoscopy* **49**: 186-190, 2016.
  26. Saito Y, Uraoka T, Yamaguchi Y, et al. A prospective, multicenter study of 1111 colorectal endoscopic submucosal dissections (with video). *Gastrointest Endosc* **72**: 1217-1225, 2010.
  27. Matsumoto A, Tanaka S, Oba S, et al. Outcome of endoscopic submucosal dissection for colorectal tumors accompanied by fibrosis. *Scand J Gastroenterol* **45**: 1329-1339, 2010.
  28. Toyonaga T, Tanaka S, Man-I M, et al. Clinical significance of the muscle-retracting sign during colorectal endoscopic submucosal dissection. *Endosc Int Open* **3**: 246-251, 2015.
  29. Lee EJ, Lee JB, Choi YS, et al. Clinical risk factors for perforation during endoscopic submucosal dissection (ESD) for large sized, nonpedunculated colorectal tumors. *Surg Endosc* **26**: 1587-1594, 2012.
  30. Kim ES, Cho KB, Park KS, et al. Factors predictive of perforation during endoscopic submucosal dissection for the treatment of colorectal tumors. *Endoscopy* **43**: 573-578, 2011.
  31. Terasaki M, Tanaka S, Shigita K, et al. Risk factors for delayed bleeding after endoscopic submucosal dissection for colorectal neoplasms. *Int J Colorectal Dis* **29**: 877-882, 2014.
  32. Ogasawara N, Yoshimine T, Noda H, et al. Clinical risk factors for delayed bleeding after endoscopic submucosal dissection for colorectal tumors in Japanese patients. *Eur J Gastroenterol Hepatol* **28**: 1407-1414, 2016.
  33. Tanaka S, Oka S, Kaneko I, et al. Endoscopic submucosal dissection for colorectal neoplasia: possibility of standardization. *Gastrointest Endosc* **66**: 100-107, 2007.
  34. Tanaka S, Oka S, Chayama K. Colorectal endoscopic submucosal dissection: present status and future prospective, including its differentiation from endoscopic mucosal resection. *J Gastroenterol* **43**: 641-651, 2008.
  35. Fujimoto K, Fujishiro M, Kato M, et al. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. *Gastrointest Endosc* **71**: 241-248, 2012 (in Japanese).
  36. Fujimoto K, Fujishiro M, Kato M, et al. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. *Dig Endosc* **26**: 1-14, 2014.
  37. Tsunada S, Ogata S, Ohyama T, et al. Endoscopic closure of perforations caused by EMR in the stomach by application of metallic clips. *Gastrointest Endosc* **57**: 948-951, 2003.
  38. Tajiri H, Katano S. Complications associated with endoscopic mucosal resection: definition of bleeding that can be viewed as accidental. *Dig Endosc* **16**: 134-136, 2004.
  39. Tanaka S, Terasaki M, Kakao H, Oka S, Chayama K. Current status and future perspectives of endoscopic submucosal dissection for colorectal tumors. *Dig Endosc* **24**: 73-79, 2012.
  40. Asayama N, Oka S, Tanaka S, et al. Endoscopic submucosal dissection as total excisional biopsy for clinical T1 colorectal carcinoma. *Digestion* **91**: 64-69, 2015.
  41. Yamashita T, Takeuchi Y, Eudo N, et al. Features of electrocoagulation syndrome after endoscopic submucosal dissection for colorectal neoplasm. *J Gastroenterol Hepatol* **31**: 615-620, 2016.
  42. Fujiya M, Tanaka K, Dokoshi T, et al. Efficacy and adverse events of EMR and endoscopic submucosal dissection for the treatment of colon neoplasms: a meta-analysis of studies comparing EMR and endoscopic submucosal dissection. *Gastrointest Endosc* **81**: 583-595, 2015.
  43. Fujishiro M, Yahagi N, Kakushima N, et al. Outcomes of endoscopic submucosal dissection for colorectal epithelial neoplasms in 200 consecutive cases. *Clin Gastroenterol Hepatol* **5**: 678-683, 2007.
  44. Takeuchi Y, Uedo N, Ishihara R, et al. Efficacy of an endo-knife with a water-jet function (Flushknife) for endoscopic submucosal dissection of superficial colorectal neoplasms. *Am J Gastroenterol* **105**: 314-322, 2010.
  45. Yoshida N, Yagi N, Naito Y, Yoshikawa T. Safe procedure in endoscopic submucosal dissection for colorectal tumors focused on preventing complications. *World J Gastroenterol* **16**: 1688-1695, 2010.
  46. Sakamoto T, Sato C, Makazu M, et al. Short-terms outcomes of colorectal endoscopic submucosal dissection performed by trainees. *Digestion* **89**: 37-42, 2014.
  47. Mizushima T, Kato M, Iwanaga I, et al. Technical difficulty according to location, and risk factors for perforation, in endoscopic submucosal dissection of colorectal tumors. *Surg Endosc* **29**: 133-139, 2015.
  48. Yamamoto H. Endoscopic submucosal dissection of early cancer and large flat adenomas. *Clin Gastroenterol Hepatol* **3**: S74-S76, 2005.
  49. Fujishiro M, Yahagi N, Kakushima N, et al. Successful nonsurgical management of perforation complicating endoscopic submucosal dissection of gastrointestinal epithelial neoplasms. *Endoscopy* **38**: 1001-1006, 2006.
  50. Fujishiro M, Iguchi M, Kakushima N, et al. Guidelines for endoscopic managements of non-variceal upper gastrointestinal bleeding. *Dig Endosc* **28**: 363-378, 2016.
  51. Niimi K, Fujishiro M, Goto O, et al. Safety and efficacy of colorectal endoscopic submucosal dissection by the trainee endoscopist. *Dig Endosc* **24** (Suppl 1): 154-158, 2012.
  52. Shiga H, Ohba R, Mastuhashi T, et al. Feasibility of colorectal endoscopic submucosal dissection (ESD) carried out by endoscopists with no or little experience in gastric ESD. *Dig Endosc* **29** (Suppl 2): 58-65, 2017.
  53. Kang DU, Choi Y, Lee HS, et al. Endoscopic and clinical factors affecting the prognosis of colorectal endoscopic submucosal dissection-related perforation. *Gut Liver* **10**: 420-428, 2016.
  54. Takamaru H, Saito Y, Yamada M, et al. Clinical impact of endoscopic clip closure of perforations during endoscopic submucosal dissection for colorectal tumors. *Gastrointest Endosc* **84**: 494-502, 2016.

55. Imai K, Hotta K, Yamaguchi Y, et al. Preoperative indicators of failure of en bloc resection or perforation in colorectal endoscopic submucosal dissection: implications for lesion stratification by technical difficulties during stepwise training. *Gastrointest Endosc* **83**: 963-965, 2016.
56. Sato K, Ito S, Kitagawa T, et al. Factors affecting the technical difficulty and clinical outcome of endoscopic submucosal dissection for colorectal tumors. *Surg Endosc* **28**: 2959-2965, 2014.
57. Lee SP, Kim JH, Sung IK, et al. Effect of submucosal fibrosis on endoscopic submucosal dissection of colorectal tumors: pathologic review of 173 cases. *J Gastroenterol Hepatol* **5**: 872-878, 2015.
58. Hayashi N, Tanaka S, Nishiyama S, et al. Predictors of incomplete resection and perforation associated with endoscopic submucosal dissection for colorectal tumors. *Gastrointest Endosc* **79**: 427-435, 2014.
59. Hong SN, Byeon JS, Lee BI, et al. Prediction model and risk score for perforation in patients undergoing colorectal endoscopic submucosal dissection. *Gastrointest Endosc* **84**: 98-108, 2016.
60. Sakamoto H, Hayashi Y, Miura Y, et al. Pocket-creation method facilitates endoscopic submucosal dissection of colorectal laterally spreading tumors, non-granular type. *Endosc Int Open* **5**: 123-129, 2017.
61. Kim EK, Han DS, Ro Y, Eun CS, Yoo KS, Oh YH. The submucosal fibrosis: what does it mean for colorectal endoscopic submucosal dissection? *Intest Res* **14**: 358-364, 2016.
62. Chiba H, Tachikawa J, Kurihara D, et al. Safety and efficacy of simultaneous colorectal ESD for large synchronous colorectal lesions. *Endosc Int Open* **5**: 595-602, 2017.

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).